Segments - Artificial Insemination Market by Type (Intrauterine Insemination, Intracervical Insemination, Intrauterine Tuboperitoneal Insemination, Intratubal Insemination, and Others), Source (Doner and Husband/Partner), End-user (Fertility Centers, Hospitals, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2024–2032
The global artificial insemination market size was USD 2.31 Billion in 2023 and is projected to reach USD 5.14 Billion by 2032, expanding at a CAGR of 9.3% during 2024–2032. The market growth is attributed to the increasing demand for advanced reproductive technologies.
Rising demand for advanced reproductive technologies is resulting in the growing use of artificial insemination, which further fuels the market. Artificial insemination techniques are becoming sophisticated and versatile, catering to diverse breeding objectives and genetic improvement programs. Additionally, expanding consumer base for artificial insemination services reflects evolving attitudes toward reproductive health, genetic selection, and sustainable agriculture practices, driving innovation and market.
The use of artificial intelligence is likely to boost the artificial insemination market. AI-powered algorithms and machine learning models analyze vast datasets to optimize breeding programs and enhance genetic selection strategies. Moreover, AI-enabled reproductive management systems offer real-time monitoring and analysis of animal health, estrus cycles, and fertility parameters.
Rising prevalence of infertility is expected to drive the market. Factors such as lifestyle changes, environmental pollution, and delayed childbearing contribute to the high incidence of infertility among men and women. Artificial insemination offers a viable solution for couples struggling with infertility by bypassing barriers to conception and facilitating successful fertilization. Additionally, the growing acceptance and accessibility of artificial insemination services boost the market during the forecast period.
According to the report published by the WHO on April 04, 2023, stating that approximately one in six adults worldwide, or 17.5% experience infertility.
Limited accessibility and affordability of artificial insemination services are anticipated to hamper the market. Factors such as inadequate infrastructure, limited veterinary artificial insemination services, and low socioeconomic status contribute to the disparity in access to artificial insemination services among smallholder farmers and rural communities. Additionally, the risk of genetic bottleneck and loss of genetic diversity associated with the widespread adoption of artificial insemination practices hinder their widespread adoption.
Increasing investments in R&D in artificial insemination techniques is creating immense opportunities for the players competing in the market. Manufacturers are focusing on investing in developing advanced semen processing technologies, cryopreservation methods, and reproductive health diagnostics. This, in turn, is creating opportunities in the market during the projected period.
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
Attributes |
Details |
Report Title |
Artificial Insemination Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2023 |
Historic Data |
2017 -2022 |
Forecast Period |
2024–2032 |
Segmentation |
Type (Intrauterine Insemination, Intracervical Insemination, Intrauterine Tuboperitoneal Insemination, Intratubal Insemination, and Others), Source (Doner and Husband/Partner), and End-user (Fertility Centers, Hospitals, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
FUJIFILM Irvine Scientific; Genea Pty Limited; Hi Tech Solutions, LLC; Innovation Works ; Kitazato Corporation; Mosie Inc; Pride Angel; Rocket Medical plc ; and Vitrolife |
Based on type, the artificial insemination market is divided into intrauterine insemination, intracervical insemination, intrauterine tuboperitoneal insemination, intratubal insemination, and others. The intrauterine insemination segment held a major share of the market in 2023, due to their widespread adoption.
Intrauterine insemination involves the direct placement of sperm into the uterus to facilitate fertilization and enhance the chances of conception. Moreover, advancements in assisted reproductive technologies and laboratory techniques have improved the success rates of intrauterine insemination procedures, further fueling the segment.
On the basis of source, the global market is bifurcated into doner and husband/partner. The husband/partner segment held the largest market share in 2023, due to the prevalent use of autologous sperm for fertility treatments and assisted reproduction procedures. Additionally, growing awareness and acceptance of fertility treatments among couples and advancements in sperm processing techniques are boosting the segment.
The donor disease segment is anticipated to expand at a substantial CAGR during the forecast period due to the increasing demand for third-party reproduction and gamete donation services. The donor source involves the use of sperm or anonymous donors to achieve pregnancy in individuals or couples facing infertility challenges. Moreover, rising infertility rates and delayed childbearing contribute to fueling the segment during the forecast period.
Based on end-user, the artificial insemination market is divided into fertility centers, hospitals, and others. The fertility centers segment led the market in terms of revenue in 2023, as they offer dedicated facilities equipped with modern laboratories, fertility clinics, and reproductive endocrinology departments. These centers attract patients seeking fertility evaluations, diagnosis, and personalized treatment plans tailored to their unique reproductive needs. Additionally, increasing awareness and acceptance of fertility treatments further propels the segment.
The hospitals segment is projected to expand at a robust pace during the assessment years, owing to their rising investments in hospital-based fertility centers and reproductive endocrinology departments. Hospitals are offering a wide spectrum of reproductive health services, including artificial insemination. Moreover, the hospital’s ability to leverage existing resources, technology, and expertise across different departments enables cost-effective delivery, which further boosts the market.
In terms of region, the global artificial insemination market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023, due to the high adoption of reproductive technologies and a strong emphasis on genetic improvement and productivity enhancement. Additionally, rise in the number of cases concerning female infertility further boosts the market.
As per the report published by the Centers for Disease Control and Prevention on April 26, 2023, approximately 19% of married women aged between 15 years and 49 years with no previous births are unable to conceive after one year of trying.
The market in Asia Pacific is projected to grow at a significant pace in the coming years, owing to the presence of diverse agricultural landscapes. This diversity creates demand for artificial insemination to cater to a wide range of livestock species and production systems, including dairy, beef, swine, and poultry. Moreover, increasing availability of affordable reproductive technologies fuel the market in this region.
The artificial insemination market has been segmented on the basis of
Key players competing in the global artificial insemination market are FUJIFILM Irvine Scientific; Genea Pty Limited; Hi Tech Solutions, LLC; Innovation Works ; Kitazato Corporation; Mosie Inc; Pride Angel; Rocket Medical plc ; and Vitrolife.
These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide.
On December 6, 2023, Mosie Inc., a pioneering company in at-home fertility, announced its Mosie Baby Kit has received clearance of FDA Class II. These kits are designed to be used for intravaginal insemination and are intended to support individuals who are unable to conceive through intercourse or for whom intercourse is not an option.